Charles River Laboratories Intl. Inc vs FuelCell Energy Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while FuelCell Energy Inc trades at $17.99 (market cap $1.47B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 9.7× FuelCell Energy Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and FuelCell Energy Inc for 48 Days on average.
| CRL | FCEL | |
|---|---|---|
Market Cap | $14.23B | $1.47B |
Volume | 1,176,885 | 12,559,948 |
Sector | Health | Industrials |
52-Week High | $310.77 | $36.01 |
52-Week Low | $149.93 | $6.00 |
Typical Hold Time | 33 Days | 48 Days |
Enterprise Value | $17.06B | $1.05B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
FCEL trades at $18.03, down 1.82% on the day, with a neutral technical signal and bearish moving averages. The company reported Q2 2026 EPS of -$0.64, missing expectations, and has negative profitability margins. Recent news highlights a securities class action lawsuit filed against the company, alleging misleading disclosures between June and September 2026.
The outlook remains challenging due to persistent losses and legal risks, though analyst consensus suggests a $21.57 price target with a mixed rating distribution. Investment opportunities hinge on future revenue growth and cost management, while risks include ongoing litigation and failure to achieve profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →